A new study reveals that many perceived benefits of gluten-free products, such as weight control and diabetes management, are ...

The prevalence of irritable bowel syndrome and chronic idiopathic constipation rose significantly during the COVID-19 pandemic.

Incidental BE was common and associated with high-risk features that were similar to or more severe than those found in BE diagnosed by traditional methods.

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

HealthDay News — The viability of hospital-based emergency care in the United States is at risk, according to a RAND report released April 7.